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Linear and cyclic hymenistatin I (HS I) analogues with dipeptide segments Ile
2
-Pro
3
,
Pro
3
-Pro
4
and Val
6
-Pro
7
replaced by their tetrazole analogues Ile
2
-[CN4]-Ala
3
,
Pro
3
-[CN4]-Ala
4
and Val
6
-[CN4]-Ala
7
were synthesized by the solid phase peptide
synthesis method and cyclized with the TBTU and/or HATU reagent. The peptides
were examined for their immunosuppressive activity in the lymphocyte proliferation
test (LPT).
A serious problem of transplantology, a dy-
namically expanding branch of contemporary
medicine, is survival of the transplanted or-
gan. A wider use of two existing and effective
immunosuppressants, cyclosporin A (CsA,
sandimmun®) [1] and FK-506 [2], as potent
drugs for the prevention of graft rejection is
limited by their side effects. In this situation,
the search for new immunosuppressants ex-
hibiting a similar mechanism of action but de-
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void of toxicity, especially in the group of nat-
urally existing immunomodulatory peptides
and their analogues, has become an important
goal for medicinal chemistry.
Hymenistatin I [HS I] is a natural cyclic octa-
peptide of the sequence cyclo(Ile1-Ile2-Pro3-
Pro4-Tyr5-Val6-Pro7-Leu8-) isolated by Petit et
al., in 1990 [3]. It has been shown by Siemion
and coworkers [4] that hymenistatin I demon-
strates some immunosuppressive activity in
respect to both humoral (PFC) and cellular
(DTH) immune response. A characteristic fea-
ture of this compound is the presence of a
cis-amide bond between Pro3-Pro4 residues, a
VIa turn in the Ile2-Tyr5 region and a I or
II turn in the Val
6
-Ile
1
region in CHCl3 and
Me2SO solution, respectively [3, 5].
To evaluate the significance of the Ile
2
-Pro
3
,
Pro3-Pro4 and Val6-Pro7 peptide bonds for HS
I biological activity, we have synthesized three
linear and three cyclic hymenistatine I ana-
logues, with the dipeptide segments Ile2-Pro3,
Pro3-Pro4 and Val6-Pro7 replaced by their
tetrazole analogues Ile2-[CN4]-Ala
3, Pro3-
[CN4]-Ala
4 and Val6-[CN4]-Ala
7, respec-
tively.
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The 1,5-disubstituted tetrazole ring,
[CN4], has been proposed as a surrogate for
cis-amide bonds, making it a valuable tool in
the design of conformationally constrained
peptidic receptor probes [6–10]. Since native
hymenistatin I has been demonstrated to have
only weak biological activity which precludes
its use as an immunosuppressant we decided
to look for immunosuppressive activity of
hymenistatin I analogues, employing a stan-
dard test used for the assessment of immuno-
suppressive activity.
MATERIALS AND METHODS
The synthesis of desired peptides
c(Ile2-[CN4]-Ala
3)HS I 8, c(Pro3-[CN4]-
Ala4)HS I 9 and c(Val6-[CN4]-Ala
7)HS I 10
as well as the native compound was achieved
by fragment condensation on a polymeric sup-
port (Merrifield type resin) using TBTU or
HATU as a coupling reagent. The synthetic
strategy is shown for peptide 8 as an example
(Fig. 2). The tetrazole building blocks 4 was
synthesized separately in solution (Fig. 1, Ta-
ble 1) following a previously reported strategy
[8, 9] and were used in the solid phase peptide
synthesis procedure. The known proclivity of
the C-terminal -carbon of tetrazole dipep-
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Figure 1. Scheme of tetrazole
tripeptides synthesis.
tides to epimerize [7–9] on prolonged base ex-
posure prompted us to omit the neutralization
step in the solid phase synthesis of peptides
containing the tetrazole unit.
The cyclization of linear precursors was per-
formed in solution using TBTU and/or HATU
as a coupling reagent (Fig. 2). The structure of
all peptides was confirmed by ESI-MS (Ta-
ble 2).
All compounds demonstrated sufficient solu-
bility and were tested for immunosuppressive
activity by the lymphocyte proliferation test
(LPT). Lymphocytes were isolated from pe-
ripheral blood of healthy volunteers. Cells
were stimulated with phytohemagglutinin
(PHA) and incubated with different concen-
trations of the agents under study or cyclo-
sporin A. Incorporation of [3H]thymidine,
which was added to the cultures 24 h before
cell harvesting, was determined in a liquid
scintillation counter and expressed as counts
per minute (c.p.m.).
RESULTS AND DISCUSSION
All synthesized analogues did not affect lym-
phocyte proliferation, thus are devoid of
immunosuppressive activity as assayed by the
LPT (Table 3). It was very surprising that
even native hymenistatin I did not affect lym-
phocyte proliferation in this kind of biological
test. On the other hand, our study does not ex-
clude that the examined compounds could
have an immunomodulatory effect on other
immunological functions. In fact it has previ-
ously been noted that the native compound
demonstrated some immunosuppressive ac-
tivity in animal models (mice). However, the
relevance of the biological activity of native
hymenistatin I described in animal models by
Cebrat et al. [4] to effective immunosuppres-
sion in humans is not clear and the lack of ef-
fect of the native compound on cytokine (IL-2
or IL-6) generation makes its clinical potential
use unlikely. Unfortunately, as demonstrated
Vol. 48 Hymenistatin I analogues 1153
Table 1. Analytical data for tetrazole tripeptides
Compound Yield [%]
[]D (c = 1,
MeOH)
tR Rf
c
Mr
d
calc./found
Boc-Ile-Ile-[CN4]-Ala-OBzl 69.9 –69.4 16.42
a
0.56
1
514.6/515.1
Boc-Ile-Pro-[CN4]-Ala-OBzl 79.8 –17.9 12.21
a
0.53
1
498.6/498.9
Boc-Tyr(2,6-diCl)-Val-[CN4]-Ala-Obzl 68.2 –53.7 17.5
a
0.64
1
697.6/698.2
Boc-Ile-Ile-[CN4]-Ala-OH 95.2 –54.8 5.46
b
0.64
2
424.5/424.8
Boc-Ile-Pro-[CN4]-Ala-OH 98.1 –16.2 5.62
b
0.58
2
408.4/409.1
Boc-Tyr(2,6-diCl)-Val-[CN4]-Ala-OH 96.4 –52.3 6.21
b
0.68
2
607.4/607.9
a
Analytical HPLC with linear gradient 50–70% B/25 min. (A) 0.05% trifluoroacetic acid in water, and (B) 0.038% trifluoroacetic
acid in acetonitrile/H2O (90:10, v/v);
b
gradient 40–60% B/25 min.
c
TLC systems: 1 = dichloromethane/acetone (30:1, v/v); 2 =
butanol/acetic acid/water (4:1:1, by vol.).
d
Relative molecular mass calculated/found by FAB-MS measurements.
Figure 2. Scheme of c(Ile
2
-[CN4]-Ala
3
)HS I syn-
thesis.
in our study, modification of hymenistatin I
by a 1,5-disubstituted tetrazole ring did not
improve its immunosuppressive activity in vi-
tro to any significant degree.
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Table 2. Analytical data for hymenistatin I analogues
Peptide Yield
a
(%) tR
b
(min) Mr
c
calc./found
5 Linear (Ile
2
-[CN4]-Ala
3
)HS I 83.1 6.37 910.07/909.87
6 Linear (Pro
3
-[CN4]-Ala
4
)HS I 90.4 9.22 910.07/910.01
7 Linear (Val
6
-[CN4]-Ala
7
)HS I 81.2 6.18 910.07/909.92
8 c(Ile
2
-[CN4]-Ala
3
)HS I 24.4 10.86 892.06/892.02
9 c(Pro
3
-[CN4]-Ala
4
)HS I 23.8 14.03 892.06/891.96
10 c(Val
6
-[CN4]-Ala
7
)HS I 21.3 10.14 892.06/892.08
a
Peptide content in crude product as shown by analytical HPLC with linear gradient 30–90% B/25 min. (A) 0.05% trifluoroacetic
acid in water, and (B) 0.038% trifluoroacetic acid in acetonitrile/H2O (90:10, v/v);
b
gradient as above;
c
relative molecular mass
calculated/found by ESI-MS measurements.
Table 3. Effect of the compounds studied on lymphocyte proliferation
Compound studied
Control solution
(PHA 10 g/ml)
2.5 g/ml 5 g/ml 10 g/ml 20 g/ml
Linear (Ile
2
-[CN4]-Ala
3
)HS I 172505 178933 169858 168503 165870
Linear (Pro
3
-[CN4]-Ala
4
)HS I 172505 186371 188707 179547 187384
Linear (Val
6
-[CN4]-Ala
7
)HS I 172505 177748 166299 154650 163309
c(Ile
2
-[CN4]-Ala
3
)HS I 200864 207386 199482 215386 227716
c(Pro
3
-[CN4]-Ala
4
)HS I 200864 206011 213888 207746 215366
c(Val
6
-[CN4]-Ala
7
)HS I 200864 207154 202170 212090 220303
Native HS I 200864 204662 211458 217956 224532
Results are shown in c.p.m. (counts per minute)
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